FindTrial
Sign In

Study on Gut Bacteria in People with Diarrhea-Predominant Irritable Bowel Syndrome (IBS)

Clinical study of Microbiome profile in Diarrhea predominant Irritable bowel syndrome (IBS) - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/03/106768
Enrollment
100
Registered
2026-03-23
Start date
Unknown
Completion date
Unknown
Last updated
2026-03-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: K580- Irritable bowel syndrome with diarrhea

Interventions

Intervention1: Nil: Nil Control Intervention1: NIL: NIL

Sponsors

Aster CMI Hospital
Lead Sponsor
Iom Bioworks Pvt Ltd
Collaborator

Eligibility

Inclusion criteria

Inclusion criteria: Participants of both genders aged 18-60 years Clinically Diagnosed IBS Type D participants BMI between 18-29.9 kg/m Willing to participate in the study over 8 weeks by providing the stool sample and other feedback as determined by the final study design Willing to undergo relevant laboratory investigations

Exclusion criteria

Exclusion criteria: Diagnosed with other chronic diseases that require treatment and hospitalization. Gastrointestinal diseases other than IBS (e.g., celiac disease or inflammatory bowel disease). Patients hospitalized, or who underwent surgeries for any disease during the past 6 months that require additional special care and that influences wellness score. E.g., fracture, dislocation etc. Patients on chemotherapy or received chemotherapy during the past 12 months. Patients on Antitubercular medications and on any long-term antibiotic courses. Patients taken antibiotics in the last 3 months. COVID-19 positive cases in the last 3 months.

Design outcomes

Primary

MeasureTime frame
1. To characterise the microbiome profile of patients with IBS Diarrhea predominant. 2. To study the differences and similarities of the characteristics with respect to a healthy cohort.Timepoint: Baseline and Post-assessment(Day 28)—

Secondary

MeasureTime frame
To correlate microbiota patterns with IBS Severity. To confirm whether gut diversity changes with regard to IBS severity. To confirm whether there is correlation between bacteria seen in previous literature & in this study s cohort. To identify novel microbiome biomarkers of dysbiosis in patients with IBS Type D.Timepoint: The 4-week visit is limited to counselling & discussion of results, with no repeat outcome assessments.—

Countries

India

Contacts

Public ContactAmit Gururaj Yelsangikar

Aster CMI Hospital

amitgy@gmail.com9742384298

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Apr 4, 2026